Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11942
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBladin, Peter Fen
dc.date.accessioned2015-05-16T01:34:34Z-
dc.date.available2015-05-16T01:34:34Z-
dc.date.issued2013-08-29en
dc.identifier.citationJournal of Clinical Neuroscience 2013; 21(1): 33-9en
dc.identifier.govdoc24238829en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11942en
dc.description.abstractThe well-established medical involvement of derivatives of the azo dye industry lent credibility to the 1935 announcement by Stanley Cobb of the use of vital brilliant red dye as an anticonvulsant. Although in the fullness of time clinical experience would discard this concept, nevertheless it was to give rise to Robert Aird who posited that the mechanism of action of this dye was due to its ability to decrease the permeability of the blood-brain barrier. In a very prolonged exploration of this concept, Aird concluded that blood-brain barrier permeability underlay the causation of a long list of chronic neurological conditions--a concept that was eventually abandoned. This article examines the details and the effects of this concept and its impact upon neurology.en
dc.language.isoenen
dc.subject.otherAnticonvulsantsen
dc.subject.otherAzo dyesen
dc.subject.otherBlood–brain barrieren
dc.subject.otherChronic neurological conditionen
dc.subject.otherAnimalsen
dc.subject.otherAnticonvulsants.pharmacologyen
dc.subject.otherAzo Compounds.history.pharmacologyen
dc.subject.otherBlood-Brain Barrier.drug effectsen
dc.subject.otherColoring Agents.history.pharmacologyen
dc.subject.otherEpilepsy.drug therapy.etiology.physiopathologyen
dc.subject.otherHistory, 20th Centuryen
dc.subject.otherHistory, 21st Centuryen
dc.subject.otherHumansen
dc.subject.otherUnited Statesen
dc.titleAzo dyes and the blood-brain barrier: Robert Aird's novel concept in chronic neurological disease (1903-2000).en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Clinical Neuroscienceen
dc.identifier.affiliationComprehensive Epilepsy Program, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1016/j.jocn.2013.06.014en
dc.description.pages33-9en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24238829en
dc.type.austinJournal Articleen
local.name.researcherBladin, Peter F
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.